Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action

Lyman, Gary H.

doi:10.1517/14712598.5.12.1635

Cited by 38 publications

(24 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been clinically proven that Neulasta has a longer half-life of t1/2 = 33 hours compared with that of t1/2 = 3.5 hours observed with filgrastin (Neupogen®), the non-nanoformulated counterpart of Neulasta, (68). A phase III clinical study compared the efficacy of Neulasta injected as a single dose with that of filgrastin administered daily in patients with breast cancer.…”

Section: Crlx-101mentioning

confidence: 99%

Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects

Alphandéry¹,

Grand-Dewyse²,

Lefèvre³

et al. 2015

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Section: Crlx-101mentioning

confidence: 99%

Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects

Alphandéry¹,

Grand-Dewyse²,

Lefèvre³

et al. 2015

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

“…A pegylated form of G-CSF, i.e. pegfilgrastim, is now available, and it contains the polyethylene glycol molecule which increases the half-life of the drug [12]. Generally, only a single injection of pegfilgrastim is required for each chemotherapy course, and several studies have shown it to be effective in reducing the duration of neutropenia as well as the rate of NF [13,14].…”

Section: Tablementioning

confidence: 99%

“…Pegfilgrastim is a recombinant long-acting G-CSF that has been shown to be as safe and effective as daily injections of filgrastim, with better patient compliance as well as lower costs [12,13,14]. To the best of our knowledge, the use of pegfilgrastim in HCL had not been described until now.…”

Section: Tablementioning

confidence: 99%

Pegfilgrastim Prophylaxis for Cladribine-Induced Neutropenia in Patients with Hairy-Cell Leukemia

Goldschmidt¹,

Ganzel²,

Attias³

et al. 2014

Acta Haematol

View full text Add to dashboard Cite

“…[23][24][25][26] The long-acting myeloid growth factor pegfilgrastim appears to have several advantages including patient convenience, improved compliance and, potentially, greater potency. 26,27 Multiple randomised controlled trials (RCTs) have consistently shown the efficacy and safety of G-CSF, which has recently been confirmed in a meta-analysis of RCTs in adult cancer patients receiving cancer chemotherapy. 28 Significant reductions in the risk of febrile neutropenia were observed across studies for both solid tumour patients and those with non-Hodgkin's lymphoma across adult age groups and all forms of G-CSF.…”

Section: Colony-stimulating Factorsmentioning

confidence: 99%

Management of Chemotherapy-induced Neutropenia with Colony-stimulating Factors

Lyman¹

2008

European Oncology &Amp; Haematology

Self Cite

View full text Add to dashboard Cite

Myelosuppression, including chemotherapy-induced neutropenia and febrile neutropenia, is the major dose-limiting toxicity of cancer chemotherapy. The myeloid colony-stimulating factors have been shown to reduce the risk of febrile neutropenia and its complications. These agents are available globally and are utilised worldwide in oncology practice to support patients receiving cancer therapy. Clinical practice guidelines are available from several international professional organisations. Chemotherapy-induced NeutropeniaFebrile neutropenia and its complications continue to be associated with substantial morbidity, mortality and cost. 1,2 Haematological toxicity associated with cancer chemotherapy occurs most frequently during the initial cycles, but varies across patient populations and treatment programmes (see Figure 1). [3][4][5] A number of studies have also indicated that chemotherapy-induced neutropenia is associated with improved treatment efficacy, presumably due to the delivered chemotherapy dose intensity. 6,7 Neutropenic complications frequently result in subsequent reductions in chemotherapy dose intensity, compromising disease-free and overall survival in patients treated with curative intent. [8][9][10][11][12] Reduced chemotherapy dose intensity appears to be more common among elderly or obese cancer patients and among certain racial and socioeconomic subgroups. 11,13-18 Risk Factors for Chemotherapy-induced Neutropenia and Its ComplicationsNeutropenic complications including febrile neutropenia, infection-related mortality and dose reductions and delays are more frequent among elderly cancer patients receiving chemotherapy. 2,17,18 While the risk of cancer increases considerably among the elderly, increasing age is associated with a reduced marrow reserve and more frequent co-morbid medical conditions accompanied by declines in renal and hepatic function, increasing the risk of treatment-related complications. [19][20][21] Other variables that increase the risk of neutropenic complications include the treatment regimen and certain patient characteristics such as functional status and medical co-morbidities. In order to more accurately predict the risk of neutropenic complications, multivariate risk models are undergoing extensive validation and may soon be available to assist clinical decision-making in oncology practice (see Figure 2). 22 Colony-stimulating FactorsThe myeloid growth factors, and most notably granulocyte colony-stimulating factor (G-CSF), have demonstrated the ability to reduce the incidence and severity of neutropenia and febrile neutropenia while improving chemotherapy dose intensity. [23][24][25][26] The long-acting myeloid growth factor pegfilgrastim appears to have several advantages including patient convenience, improved compliance and, potentially, greater potency. 26,27 Multiple randomised controlled trials (RCTs) have consistently shown the efficacy and safety of G-CSF, which has recently been confirmed in a meta-analysis of RCTs in adult cancer patients receiving cance...

show abstract

Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action

Cited by 38 publications

References 43 publications

Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects

Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects

Pegfilgrastim Prophylaxis for Cladribine-Induced Neutropenia in Patients with Hairy-Cell Leukemia

Management of Chemotherapy-induced Neutropenia with Colony-stimulating Factors

Contact Info

Product

Resources

About